Two deaths, dozens of severe injuries, and yet the so-called “experts” still won’t pull these deadly Baxter infusion pumps from our nation’s hospitals—how much more “safety” can Americans and their loved ones stand?
At a Glance
- Baxter’s Novum IQ infusion pumps have been tied to two patient deaths and 79 severe injuries from dosing errors.
- The FDA and Health Canada both issued urgent Class I recall alerts, but the devices remain in use with only updated instructions.
- Hospitals must retrain staff and scramble for workarounds, while Baxter and regulators avoid full accountability.
- Experts warn mitigation steps may not go far enough to protect vulnerable patients from further harm.
Two Deaths, 79 Severe Injuries, and Bureaucratic Inertia
Hospitals across the United States and Canada are still using the Baxter Novum IQ infusion pump, even after the device was directly linked to two deaths and at least 79 severe injuries from critical dosing errors. The FDA and Health Canada responded with their highest-level Class I recall warnings in July 2025, but—get this—the so-called “recall” didn’t actually remove the pumps from service. Instead, hospitals were told to read some new instructions, retrain exhausted staff, and keep using the same machines that have already proven deadly. The American people deserve to know why bureaucrats and corporate executives keep dodging responsibility while vulnerable patients pay the price.
🚨 FDA warns Baxter’s Novum IQ infusion pumps may cause over/underinfusion due to flow rate changes or tubing misloads. 79 injuries & 2 deaths reported. Affected users urged to act now.
Source: FDA https://t.co/nyooX0RB5E pic.twitter.com/6GBAyAPL46— AmericanFrontlineNurses (@AFLN2021) July 27, 2025
These pumps—used to deliver lifesaving fluids and medications to babies, ICU patients, and the critically ill—were supposed to represent the latest in medical technology. But reports started pouring in earlier this year that the Novum IQ’s supposedly “precise” dosing could go haywire, either dumping too much or too little medication into a patient’s body. The worst failures happened during certain transitions in flow rates or when pumps were improperly loaded, both situations that ought to have been anticipated and engineered out of the device. Instead, the risk landed squarely on patients and overworked healthcare professionals.
Watch: A nurse’s perspective on the Novum IQ Syringe Pump – 3
Regulators Issue Warnings, But Devices Stay in Hospitals
As of July, more than 34,500 Novum IQ pumps were still in operation in North America. When the FDA and Health Canada finally acted, the public expected decisive action. Instead, Baxter issued a letter recommending “mitigation steps” and “updated instructions for use.” Hospitals were told to switch to alternative pumps if possible, but the Novum IQs were not pulled from service. This is the government’s idea of “top-level safety action”: issue a warning, push paperwork, and leave the problem in the hands of the very hospitals that bought these devices in the first place.
Hospitals Left Carrying the Burden and the Risk
Doctors, nurses, and hospital administrators have been left holding the bag. They’re now scrambling to implement new procedures, retrain staff, and monitor for errors—all while still depending on the same suspect equipment. The American taxpayer pays for these hospitals, pays for the training, pays for the lawsuits, and in the end, pays for the mistakes of corporate America and its regulatory enablers. Meanwhile, Baxter gets to keep its product on the shelves, shifting the blame onto the users for “not following instructions” if, heaven forbid, another tragedy occurs.
Experts in medical device safety have publicly questioned whether Baxter’s steps go far enough. Some clinicians want the devices immediately replaced, especially for the most vulnerable patients, while others say there simply aren’t enough alternatives available. The debate exposes a broken system: big business designs and markets high-risk devices, government agencies issue toothless warnings, and patients keep suffering. The FDA and Health Canada can call it a recall all day long, but if the device stays in use, what’s really being “recalled” is the public’s trust in the whole process.
